J&J bumps up full-year profit view on strength of cancer drugs




J&J bumps up full-year profit view on strength of cancer drugs
J&J bumps up full-year profit view on strength of cancer drugs  

(Reuters) - Johnson & Johnson <JNJ.N> on Tuesday boosted its full-year adjusted profit forecast, as multi-billion dollar sales of its cancer drugs Darzalex and Imbruvica helped it beat estimates for third-quarter profit.

Shares of the company rose 2% to $133.48 in premarket trading.

J&J did not report litigation expenses for the third quarter and its legal expenses over the nine-month period remained at $832 million, as was reported at the end of the second quarter.

The company is facing more than 13,000 lawsuits tied to antipsychotic drug Risperdal as well as a range of lawsuits involving its baby powder, opioids, medical devices and other products.

J&J on Tuesday said it now expects full-year adjusted earnings per share in the range $8.62 to $8.67, from its prior forecast of $8.53 to $8.63. Analysts were expecting $8.60 per share.

Net earnings rose to $4.83 billion, or $1.81 per share, in the quarter, from $3.93 billion, or $1.44 per share, a year earlier.

Excluding items, the company earned $2.12 per share, beating analysts' expectations of $2.01 per share, according to IBES data from Refinitiv.

Total sales rose 1.9% to $20.73 billion, above the average analysts' estimate of $20.07 billion.


(Reporting by Saumya Sibi Joseph and Ankur Banerjee in Bengaluru; Editing by Bernard Orr)

COMMENTS

More Related News

Judge lowers opioid settlement to $465 million, blames error
Judge lowers opioid settlement to $465 million, blames error

An Oklahoma judge who had ordered Johnson & Johnson to pay $572 million for its role in the opioid crisis on Friday reduced the figure to $465 million, after a miscalculation. Judge Thad Balkman in August ordered the pharmaceutical giant to pay Oklahoma $572 billion to finance an "abatement plan" for care for addicts, families and communities ravaged by the crisis that's led to more than 400,000 overdose deaths in the United States since 1999.

Oklahoma judge reduces J&J order in opioid lawsuit by $107M
Oklahoma judge reduces J&J order in opioid lawsuit by $107M

An Oklahoma judge who last summer ordered consumer products giant Johnson & Johnson to pay $572 million to help address the state's opioid crisis on Friday reduced that amount by $107 million in a final order in the case. District Judge Thad Balkman's latest order directs the company to pay the state $465 million. In it, Balkman acknowledged that he miscalculated in his original award how much it would cost to develop a program for treating babies born addicted to opioids.

Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million
Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million
  • US
  • 2019-11-15 20:07:17Z

The decision by Cleveland County District Judge Thad Balkman in Norman, Oklahoma, came in the first case to go to trial out of 2,700 nationally by states, counties and cities seeking to hold drug companies responsible for the deadly epidemic. Balkman reduced the amount he had awarded in August by $107 million after agreeing with New Brunswick, New Jersey-based J&J that he had made a math error. A spokesman for Oklahoma Attorney General Mike Hunter said that office is reviewing the decision and will formally respond within the next few days.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Economy